The aims of this study were to investigate the safety of combined intravenous, oral and topical tranexamic acid (TXA) in primary total knee replacement. We assessed dose-related efficacy on hemoglobin level, transfusion, length of stay and thromboembolic complications. In addition, TXA safety in patients with previous history of thromboembolism >12 months ago was monitored specifically.
From January 2013 until January 2016, 922 patients were included who received TXA after primary total knee replacement. Patients without TXA administration or with thromboembolic events <12 months ago were excluded. TXA dosage groups were divided into ≤10 mg/kg, >10–25 mg/kg and >25–50 mg/kg.
Between the three TXA groups no significant difference was found in thromboembolic complications (deep venous thrombosis (DVT) and pulmonary embolism (PE)), wound leakage and transfusion rate. For patients with DVT or PE in their history >12 months ago specifically, no more complications were noted in higher-TXA-dosage groups compared to the low-dosage group. Length of stay was shorter in the highest-TXA-dosage group compared with lower-dosage groups (median two vs three days). With high TXA dose a smaller difference between pre- and postoperative Hb was found: the >25–50 mg/kg TXA group had a 0.419 mmol/l smaller decrease in postoperative hemoglobin compared to the lowest-dosage group (P < 0.05).
Combined intravenous, oral and topical TXA is effective in knee replacement and can safely be given to patients with a thromboembolic history >12 months ago. High dosage (>25–50 mg/kg) TXA resulted in the smallest decrease in postoperative hemoglobin.